Gastrointestinal endoscopy devices and the European Union Medical Device Regulation: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement.

Gastrointestinal endoscopy is largely dependent on medical devices. The European Union (EU) has recently introduced stricter rules and regulations for the approval of medical devices. This has consequences both for endoscopists and for patients. The new regulations increase the need for clinical trials and observational studies for new and current devices used in endoscopy to ensure clinical benefit and reduce patient harm. European endoscopy environments should facilitate industry-sponsored clinical trials and registry studies to meet the demand for robust data on endoscopic devices as required in the new legislation. The European Society of Gastrointestinal Endoscopy (ESGE) will play an active role in the establishment of the new system.The EU is establishing independent expert panels for device regulation in gastroenterology and hepatology, including endoscopy, that are charged with assessing the requirements for device testing. The ESGE encourages endoscopists with expertise in the technical and clinical performance of endoscopy devices to apply for expert panel membership. The ESGE has provided information for interested endoscopists on the ESGE website. Private European companies called "notified bodies" are entitled to conduct device approval for the EU. The ESGE will actively engage with these notified bodies for topics related to the new endoscopy device approval process to ensure continued access to high quality endoscopy devices for endoscopists in Europe.

Informations de copyright

European Society of Gastrointestinal Endoscopy. All rights reserved.

Déclaration de conflit d'intérêts

R. Bisschops has received speaker’s and consultancy fees and research grants from Fujifilm, Pentax, Medtronic, and Norgine, consultancy fees from GI supply, CDX diagnostics, Boston Scientific, and Cook, and speaker’s fees from Ipsen and Medivators. M. Bretthauer has received research support (loaned devices) from Olympus Corporation, and has provided consultancy to Paion (expert testimony) and Cybernet System. I.M. Gralnek has received research support from Astra-Zeneca and Check Cap, and has provided consultancy to Boston Scientific, Medtronic, Clexio Biosciences, Motus GI, Vifor Pharma, Neurogastrx, and Simbionix; he is on the medical advisory board of Motus GI. C. Hassan has received research support from Fujifilm and Medtronic, and has provided consultancy to Alpha-sigma Norgine, Olympus, Ambu, Boston Scientific, Covidien, and Takeda. H. Messmann has received research grants from Olympus and Satisfai, and lecture fees from Dr. Falk Pharma, Olympus, Norgine, IPSEN, Medupdate, and Erbe. Y. Mori has had loaned devices and received consultancy and speaker’s fees from Olympus; he has an ownership interest in Cybernet System. P.D Siersema has received research support from Pentax, The E-Nose company, Lucid Diagnostics-US, Micro Tech, Motus GI, Magentiq Eye, Norgine, and Endo Tools Therapeutics, and consultancy fees from Motus GI and Magentiq Eye. M.F. Kaminski, T. Ponchon, and J. Zessner-Spitzenberg declare that they have no conflict of interest.